Biochimica et biophysica acta. Molecular basis of disease · 2026
Hepatic methionine-cycle dysregulation is associated with immune-inflammatory and fibrogenic remodeling in biliary atresia.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lv Chao, Dai Xiaoke, Wang Haoming, Gao Xiaolei, Tan Bingqian, Yang Chenyu, Zhao Yao, Zhang Mingman
Аннотация
BACKGROUND: Biliary atresia (BA) is a progressive fibroinflammatory cholangiopathy leading to liver failure in infancy. The contribution of methionine metabolism to BA remains incompletely defined. This study investigated hepatic methionine-cycle alterations and the potential therapeutic effects of S-adenosylmethionine (SAMe).
METHODS: Public bulk transcriptomic and single-cell RNA sequencing datasets were analyzed to characterize methionine-cycle-related alterations in BA. Selected genes were validated in clinical liver tissues. Methionine-cycle metabolites, oxidative stress indicators, and histopathological changes were assessed in human liver samples. The effects of SAMe were examined in BA-derived liver mononuclear cells (LMNCs) and further evaluated in a rhesus rotavirus-induced BA mouse model using methionine-cycle metabolite quantification, liver transcriptomics, multiplex immunofluorescence, cytokine measurement, oxidative stress assays, and histological analysis.
RESULTS: Methionine metabolism-related genes were dysregulated in BA, highlighting alterations in the one-carbon-methionine cycle-transsulfuration axis. Single-cell analysis localized these alterations to both hepatocyte and immune-cell compartments. Human BA liver tissues exhibited methionine-cycle imbalance, with increased methionine, S-adenosylhomocysteine, and homocysteine levels and reduced S-adenosylmethionine levels, accompanied by oxidative stress and fibrogenic responses. SAMe modulated cytokine secretion in BA-derived LMNCs. In BA mice, SAMe partially normalized methionine-cycle metabolite levels, improved hepatic redox status, reduced inflammatory immune infiltration, attenuated cytokine responses, and alleviated early fibrogenic remodeling.
CONCLUSIONS: Hepatic methionine-cycle dysregulation is a prominent metabolic feature of BA and is associated with oxidative stress, immune-inflammatory alterations, and fibrogenic remodeling. SAMe partially alleviated these abnormalities in ex vivo and animal-model experiments, supporting further investigation of the therapeutic relevance of methionine metabolism in BA.
METHODS: Public bulk transcriptomic and single-cell RNA sequencing datasets were analyzed to characterize methionine-cycle-related alterations in BA. Selected genes were validated in clinical liver tissues. Methionine-cycle metabolites, oxidative stress indicators, and histopathological changes were assessed in human liver samples. The effects of SAMe were examined in BA-derived liver mononuclear cells (LMNCs) and further evaluated in a rhesus rotavirus-induced BA mouse model using methionine-cycle metabolite quantification, liver transcriptomics, multiplex immunofluorescence, cytokine measurement, oxidative stress assays, and histological analysis.
RESULTS: Methionine metabolism-related genes were dysregulated in BA, highlighting alterations in the one-carbon-methionine cycle-transsulfuration axis. Single-cell analysis localized these alterations to both hepatocyte and immune-cell compartments. Human BA liver tissues exhibited methionine-cycle imbalance, with increased methionine, S-adenosylhomocysteine, and homocysteine levels and reduced S-adenosylmethionine levels, accompanied by oxidative stress and fibrogenic responses. SAMe modulated cytokine secretion in BA-derived LMNCs. In BA mice, SAMe partially normalized methionine-cycle metabolite levels, improved hepatic redox status, reduced inflammatory immune infiltration, attenuated cytokine responses, and alleviated early fibrogenic remodeling.
CONCLUSIONS: Hepatic methionine-cycle dysregulation is a prominent metabolic feature of BA and is associated with oxidative stress, immune-inflammatory alterations, and fibrogenic remodeling. SAMe partially alleviated these abnormalities in ex vivo and animal-model experiments, supporting further investigation of the therapeutic relevance of methionine metabolism in BA.